Trials / Unknown
UnknownNCT04571372
Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 19 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)
Conditions
Timeline
- Start date
- 2020-09-23
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2020-10-01
- Last updated
- 2020-11-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04571372. Inclusion in this directory is not an endorsement.